HUTCHMED (China) Limited Stock

Equities

HCM

KYG4672N1198

Pharmaceuticals

Market Closed - London S.E. 11:35:23 2024-05-03 am EDT 5-day change 1st Jan Change
310 GBX 0.00% Intraday chart for HUTCHMED (China) Limited +6.90% +9.54%
Sales 2024 * 681M Sales 2025 * 836M Capitalization 3.32B
Net income 2024 * -109M Net income 2025 * -5M EV / Sales 2024 * 4.58 x
Net cash position 2024 * 199M Net cash position 2025 * 306M EV / Sales 2025 * 3.61 x
P/E ratio 2024 *
-28.7 x
P/E ratio 2025 *
604 x
Employees 1,988
Yield 2024 *
-
Yield 2025 *
-
Free-Float 52.37%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on HUTCHMED (China) Limited

1 week+6.90%
Current month+4.20%
1 month+14.81%
3 months+60.62%
6 months-3.43%
Current year+9.54%
More quotes
1 week
292.00
Extreme 292
316.00
1 month
260.00
Extreme 260
316.00
Current year
190.40
Extreme 190.4
316.00
1 year
173.60
Extreme 173.6
338.00
3 years
130.00
Extreme 130
656.00
5 years
130.00
Extreme 130
656.00
10 years
74.00
Extreme 74
656.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 66 04-12-31
Director of Finance/CFO 57 08-06-30
Chief Tech/Sci/R&D Officer 59 21-12-31
Members of the board TitleAgeSince
Chairman 72 99-12-31
Director/Board Member 73 17-02-28
Director/Board Member 70 16-07-31
More insiders
Date Price Change Volume
24-05-03 310 0.00% 17,440
24-05-02 310 +3.33% 261,433
24-05-01 300 +0.84% 75,647
24-04-30 297.5 -2.14% 123,751
24-04-29 304 +4.83% 92,539

Delayed Quote London S.E., May 03, 2024 at 11:35 am EDT

More quotes
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.891 USD
Average target price
5.386 USD
Spread / Average Target
+38.42%
Consensus

Quarterly revenue - Rate of surprise